Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes

被引：24
作者：
Peacock, Sharon C. [1 ]
Lovshin, Julie A. [2 ,3 ]
Cherney, David Z. I. [3 ,4 ]
机构：
[1] Univ Toronto, Dept Anesthesiol, Toronto, ON, Canada
[2] Toronto Gen Hosp, Dept Med, Div Endocrinol, Toronto, ON, Canada
[3] Univ Toronto, Banting & Best Diabet Ctr, Dept Physiol, Toronto, ON, Canada
[4] Toronto Gen Hosp, Div Nephrol, Dept Med, Toronto, ON, Canada
来源：
ANESTHESIA AND ANALGESIA | 2018年 / 126卷 / 02期
关键词：
DOUBLE-BLIND; EMPAGLIFLOZIN; KETOACIDOSIS; ASSOCIATION; MANAGEMENT; OUTCOMES;
D O I：
10.1213/ANE.0000000000002377
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
[No abstract available]
引用
收藏
页码：699 / 704
页数：6
相关论文
共 26 条
[1]   5. Glycemic Targets [J].
不详 .
DIABETES CARE, 2016, 39 :S39-S46
[2]  
[Anonymous], FDA DRUG SAF COMM FD
[3]   Peri-operative management of the surgical patient with diabetes 2015: Association of Anaesthetists of Great Britain and Ireland [J].
Barker, P. ;
Creasey, P. E. ;
Dhatariya, K. ;
Levy, N. ;
Lipp, A. ;
Nathanson, M. H. ;
Penfold, N. ;
Watson, B. ;
Woodcock, T. .
ANAESTHESIA, 2015, 70 (12) :1427-1440
[4]   Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update Canadian Diabetes Association Clinical Practice Guidelines Expert Committee [J].
Booth, Gillian ;
Lipscombe, Lorraine ;
Butalia, Sonia ;
Dasgupta, Kaberi ;
Eurich, Dean ;
Goldenberg, Ronald ;
Khan, Nadia ;
MacCallum, Lori ;
Shah, Baiju ;
Simpson, Scot ;
Houlden, Robyn L. .
CANADIAN JOURNAL OF DIABETES, 2016, 40 (06) :484-486
[5]   Sotagliflozin as a potential treatment for type 2 diabetes mellitus [J].
Cariou, Bertrand ;
Charbonnel, Bernard .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (12) :1647-1656
[6]   The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes [J].
Cherney, David ;
Lund, Soren S. ;
Perkins, Bruce A. ;
Groop, Per-Henrik ;
Cooper, Mark E. ;
Kaspers, Stefan ;
Pfarr, Egon ;
Woerle, Hans J. ;
von Eynatten, Maximilian .
DIABETOLOGIA, 2016, 59 (09) :1860-1870
[7]   Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program [J].
Erondu, Ngozi ;
Desai, Mehul ;
Ways, Kirk ;
Meininger, Gary .
DIABETES CARE, 2015, 38 (09) :1680-1686
[8]  
FDA, 2014, INV CAN HIGHL PRESCR
[9]  
FDA, HIGHL PRESCR INF INV
[10]   CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis [J].
Ferrannini, Ele ;
Mark, Michael ;
Mayoux, Eric .
DIABETES CARE, 2016, 39 (07) :1108-1114
123